Peter M. Grace, Ph.D.
Department of Symptom Research, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Department Chair ad interim, Translational Neuroscience, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2011 | University of Adelaide, Adelaide, AU, Ph.D. in Clinical and Experimental Pharmacology |
| 2006 | University of Adelaide, Adelaide, AU, Honors in Health Sciences |
| 2005 | University of Adelaide, Adelaide, AU, BS in Pharmacology |
Postgraduate Training
| 2024-2024 | LEADing Teams, MD Anderson Leadership Institute, Houston, Texas |
| 2021-2021 | LEADing Others Accelerate, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2020 | Life Science I-Corps Regional Program, MD Anderson Center for Entrepreneurship Advancement, Houston, Texas |
| 2019-2019 | Research Mentor Training for Faculty, National Research Mentoring Network and Gulf Coast Consortium, Houston, Texas |
| 2019-2019 | Postgraduate Fellow, MD Anderson Leadership Institute, Houston, Texas |
| 2019-2019 | LEADing Others, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2017 | Faculty Supervision and Management, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2014 | Research Fellowship, University of Colorado Boulder, Boulder, Colorado |
| 2011-2011 | Winter School in Mathematical and Computational Biology, University of Queensland, Brisbane |
Licenses & Certifications
| 2024 | LEADing Teams |
| 2021 | LEADing Others Accelerate |
| 2020 | Life Science I-Corps Regional Program |
| 2019 | LEADing Others |
| 2019 | Research Mentor Training for Faculty |
| 2016 | Faculty Supervision and Management |
| 2011 | Winter School in Mathematical and Computational Biology |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Translational Neuroscience, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2022
Research Assistant Professor, University of Colorado Boulder, Boulder, CO, 2015 - 2016
Administrative Appointments/Responsibilities
Director, CCSG Preclinical Behavior Core, University of Texas MD Anderson Cancer Center, 2025 - Present
Associate Leader, CCSG Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Neurotoxicity Theme Director, Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Other Professional Positions
Chair, Scientific Programming Committee Member, US Association for the Study of Pain, 2024 - 2025
Scientific Programming Committee Member, MD Anderson Cancer Center, 2024 - 2025
Scientific Programming Committee Member, US Association for the Study of Pain, Online, 2022 - 2025
Education and Professional Development Committee Member, US Association for the Study of Pain, Online, 2021 - 2023
Chair, Gulf Coast Consortium for Translational Pain Research, 2021 - 2023
Board of Directors (elected), PsychoNeuroImmunology Research Society, Houston, TX, 2019 - 2023
Scientific Affairs Committee Member, Next Generation Pain Therapeutics: From Discovery to the Clini, Houston, TX, 2019 - 2020
Executive Committee Member, Gulf Coast Consortium for Translational Pain Research, 2018 - Present
Scientific Affairs Committee Member, PsychoNeuroImmunology Research Society, 2018 - 2022
Membership Committee Member, PsychoNeuroImmunology Research Society, 2017 - 2022
Clinical Research Assistant, Pain & Anaesthesia Research Clinic, Adelaide, 2006 - 2011
Extramural Institutional Committee Activities
Advisory Board, MD Anderson NeuroHealth Initiative, The University of Texas MD Anderson Cancer Center, 2024 - Present
Program Lead, Cancer Neuroscience, The University of Texas MD Anderson Cancer Center, 2024 - Present
Executive Committee, MD Anderson Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Hospital Medicine Department Chair Advisory Committee, The University of Texas MD Anderson Cancer Center, 2022
Reviewer (ad hoc), Center for Advanced Biomedical Imaging Pilot Project Program Grant, The University of Texas MD Anderson Cancer Center, 2021
Junior Faculty Steering Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Executive Committee Member, MD Anderson Pain Research Consortium, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Committee Member, Junior Faculty Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Facilitator, Pain and Brain Health Seminar Series, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Reviewer (ad hoc), CCSG Technology Development Grants, The University of Texas MD Anderson Cancer Center, 2019
Executive Committee Member, Cancer Neuroscience Initiative, The University of Texas MD Anderson Cancer Center, 2018 - 2021
Member (ad hoc), Search Committee, Department of Symptom Research, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2018
Review Panelist, Biomedical Sciences Grant Review, Innovative Seed Grant Program, University of Colorado Boulder, The University of Texas MD Anderson Cancer Center, 2013
Editorial Activities
Associate Editor, Brain, Behavior, and Immunity, 2024 - Present
Associate Editor, Pain Reports, 2024 - Present
Associate Editor, Brain, Behavior, and Immunity – Health, 2023 - 2024
Editorial Board Member, Journal of Pain, 2022 - Present
Guest Editor, Brain, Behavior, and Immunity; Special Issue on Neuroimmunology of pain and analgesia, 2022
Editorial Board Member, Neurobiology of Pain, 2021 - Present
Editorial Board Member, Frontiers in Pain Research, 2020 - 2022
Editorial Board Member, Brain, Behavior, and Immunity-Health, 2019 - 2023
Guest Editor, Proceedings of the National Academy of Sciences USA, 2019
Editorial Board Member, Brain, Behavior, and Immunity, 2016 - Present
Honors & Awards
| 2025 | Visiting Professor, Australian Northern Communities Health and Research Foundation |
| 2024 | Excellence in Leadership Award, MD Anderson |
| 2022 | President’s Recognition of Faculty Excellence in Research, MD Anderson Cancer Center |
| 2022 | Faculty Excellence in Research Award, Division of Internal Medicine, MD Anderson Cancer Center |
| 2019 - 2022 | Rita Allen Foundation Award in Pain, Rita Allen Foundation |
| 2019 - 2021 | NARSAD Young Investigator Award |
| 2019 | Centre for Nanoscale BioPhotonics Commercial Impact Award |
| 2018 | Robert Ader New Investigator Award, PsychoNeuroimmunology Research Society |
| 2017 | Rising STARs Award, University of Texas |
| 2015 | Trainee Scholar Award, PsychoNeuroImmunology Research Society |
| 2014 | Trainee Scholar Award, PsychoNeuroImmunology Research Society |
| 2014 | Travel Grant, International Association for the Study of Pain |
| 2014 | Young Investigators Travel Award, American Pain Society |
| 2014 | Future Leaders in Pain Research Award, American Pain Society |
| 2014 | Oral Presentation Winner, Front Range Neuroscience Group |
| 2014 | Best Data Blitz Presentation, American Pain Society |
| 2013 - 2016 | CJ Martin Overseas Biomedical Fellowship (Postdoctoral), Australian National Health and Medical Research Council |
| 2013 | Sir Keith Murdoch Fellowship (Postdoctoral), American Australian Association |
| 2013 | Trainee Scholar Award, PsychoNeuroImmunology Research Society |
| 2011 | Dean's Commendation for Doctoral Thesis Excellence, Dean of Graduate Studies, University of Adelaide |
| 2011 - 2010 | Fresh Science Australia Runner-up |
| 2010 | Best Oral Communication, Adelaide Pharmacology Group |
| 2010 | Best Free Paper Award, Oral Communication, Australian Pain Society/ New Zealand Pain Society Combined Scientific Meeting |
| 2010 | Research Prize, Best Oral Communication, Royal Adelaide Hospital Medical Staff Society |
| 2009 - Present | Toxicology Travel Award, Australasian Society of Clinical & Experimental Pharmacology |
| 2009 | Faculty of Health Sciences Postgraduate Travel Grant, University of Adelaide |
| 2008 - Present | Toxicology Travel Award, Australasian Society of Clinical & Experimental Pharmacology |
| 2007 | Divisional Ph.D. Scholarship, Faculty of Health Sciences, University of Adelaide |
| 2006 | Toxicology Travel Award, Australasian Society of Clinical & Experimental Pharmacology |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Targeting Neuroimmune Signaling Pathways for Novel Analgesics. Invited. MD Anderson Cancer Center, Cancer Biology Seminar Series. Houston, Texas, US.
- 2025. Dead cells and dangerous IgG: autoimmune signaling driving neuropathic pain. Invited. College Station, TX, US.
- 2024. Targeting NRF2 to alleviate neuropathic pain. Invited. Houston, TX, US.
- 2024. The University of Texas Systemwide Brain Research Summit, Symposium on Innovations in the Neurobiology and Management of Pain. Invited. Pain therapeutics development in Texas: entrepreneurship and industry collaboration. Austin, Texas, US.
- 2024. Peripheral neuroimmunology of pain associated with cancer treatment. Invited. Houston, Texas, US.
- 2023. HDAC6 inhibitors as novel drug candidates to reverse chemotherapy-induced neuropathy. Invited. Houston, Texas, US.
- 2022. Chronic pain as a complication of cancer treatment: new therapeutic avenues. Houston, Texas, US.
Regional Presentations
- 2025. Selectively targeting oxidative stress hotspots for treatment of neuropathic pain. Invited. San Diego, CA, US.
- 2025. Regulation of neuropathic pain by B cells. Invited. Pittsburgh, PA, US.
- 2025. Regulation of neuropathic pain by B cells. Invited. Storrs, CT, US.
- 2024. Regulation of neuropathic pain by B cell. Invited. Virtual, US.
- 2024. B lymphocytes regulate neuropathic pain after peripheral nerve injury. Invited. Chicago, IL, US.
- 2024. HDAC6 inhibitors as novel drug candidates to reverse chemotherapy-induced mechanical pain. Invited. Houston, TX, US.
- 2024. “Regulation of Neuropathic Pain by B cells. Invited. Houston, TX, US.
- 2024. B cell regulation of neuropathic pain. Invited. Houston, TX, US.
- 2022. Current state of pain research in Texas. Invited. Austin, TX, US.
- 2022. Activating endogenous antioxidant signaling to relieve neuropathic pain. Invited, US.
- 2020. Resolution of neuropathic pain and oxidative stress via activation of Nrf2. Invited. Houston, TX, US.
- 2020. Opioids and pain persistence: a role for neuroimmune mechanisms. Invited. Virtual, US.
- 2020. Targeting Nrf2 to alleviate neuropathic pain. Invited. Dallas, TX, US.
- 2019. Fumaric acid esters alleviate neuropathic pain via Nrf2. Invited. San Antonia, TX, US.
- 2019. Targeting the neuroimmune interface to treat persistent pain. Invited. Auatin, TX, US.
- 2019. Neuroimmune signaling in pain: opportunities for therapeutic intervention. Invited. Galveston, TX, US.
- 2018. The role of neuroimmune signaling in the transition from acute to chronic pain. Invited. Houston, TX, US.
National Presentations
- 2026. Dead cells and dangerous IgG: autoimmune signaling driving neuropathic pain. Oklahoma State University Anatomy and Cell Biology Seminar Series. Tulsa, Oklahoma, US.
- 2025. Cross-Species Validation of B Cell-Mediated Neuropathic Pain: From Rodents to Pigs and Beyond. Invited. Bethesda, MD, US.
- 2024. NIH HEAL Pain Strategic Planning, Biomarkers and Predictors workshop. Invited. Virtual, US.
- 2024. B cell regulation of neuropathic pain. Invited. Lloyd Harbor, NY, US.
- 2024. Regulation of neuropathic pain by B cells. Invited. Minneoplpolis, MN, US.
- 2023. Neuroimmune mechanisms of pain: opportunities for therapeutic intervention. Invited. Tampa, FL, US.
- 2023. B Cell Regulation of Neuropathic Pain. Invited. Fort Collins, CO, US.
- 2023. B Cell Regulation of Neuropathic Pain. Invited. Boulder, CO, US.
- 2023. Pathology-activated prodrugs for treatment of diseases and disorders of oxidative stress. Invited. Aurora, CO, US.
- 2023. HDAC6 inhibitors as novel drug candidates to reverse chemotherapy-induced neuropathy. Invited. Virtual, US.
- 2023. Neuroimmune mechanisms of neuropathic pain: opportunities for therapeutic intervention. Invited. Salt Lake City, US.
- 2022. Neuroimmune mechanisms of pain: opportunities for therapeutic intervention. Invited. Columbus, OH, US.
- 2022. B cell regulation of neuropathic pain. Invited. Durham, NC, US.
- 2022. Antibody receptor signaling via astrocytes: a new pathway for neuropathic pain. Invited. Cinncinatti, OH, US.
- 2022. Neuroimmune mechanisms of neuropathic pain and its relief. Invited. New York City, NY, US.
- 2021. Targeting Nrf2 to alleviate neuropathic pain. Invited. Virtual, US.
- 2020. Fcγ receptor signaling and neuropathic pain. Invited. Virtual, US.
- 2020. Neuroimmune interactions in neuropathic pain: emerging mechanisms and therapeutic targets. Invited. Boulder, CO, US.
- 2020. A role for Nrf2 in alleviating neuropathic pain. Invited. Kansas City, KS, US.
- 2019. Repurposing The Nrf2 Activator Dimethyl Fumarate (Tecfidera) For Treatment Of Pain Due To Traumatic Nerve Injury In Male Rats. Invited. Orlando, FL, US.
- 2019. Alleviating neuropathic pain and inflammasome activation via Nrf2. Invited. Milwaukee, WI, US.
- 2019. Targeting the neuroimmune interface to treat persistent pain. Invited. Cincinnati, OH, US.
- 2018. Targeting the neuroimmune interface to treat persistent pain. Invited. Tucson, AZ, US.
- 2018. Neuroimmune mechanisms of neuropathic pain prevention by exercise. Invited. Boston, MA, US.
- 2018. Networking: the what, why and how. Invited. Miami, FL, US.
- 2018. Neuroimmune crosstalk and pain. Invited. Miami, FL, US.
- 2017. Neuroimmune mechanisms of chronic pain: implications for Gulf War illness. Invited. Palo Alto, CA, US.
- 2017. Morphine and pain persistence: a role for neuroimmune signaling. Invited. Big Sky, MT, US.
- 2016. Neuroimmune signaling: a regulator of the severity and duration of pathological pain. Invited. Columbus, OH, US.
- 2015. DREADDed microglia in pain: implications for inflammatory signaling. Invited. Seattle, WA, US.
- 2015. DREADDed microglia in pain: implications for inflammatory signaling. Invited. Palm Springs, CA, US.
- 2015. The role of microglia in the transition from acute to chronic pain. Invited. Department of Pharmacological & Physiological Sciences Colloquium. St. Louis, MO, US.
- 2015. The ‘Toll’ of pain: a role for the innate immune receptor TLR4. Invited. Miami, FL, US.
- 2015. The role of microglia in the transition from acute to chronic pain. Invited. Department of Neurosciences Colloquium. Albuquerque, NM, US.
- 2012. “Neuroimmunopharmacology of opioids and alcohol: behavioral, cellular signaling and binding evidence for a role for Toll like receptors. Invited. Phoenix, AZ, US.
International Presentations
- 2026. Dead cells and dangerous IgG: autoimmune signaling driving neuropathic pain. Invited. ResolvePAIN Seminar Series. wurzburg, DE.
- 2026. From Damage to Dialogue: How Neuroimmune Communication Shapes Peripheral Nerve Repair and Pain. Invited.
- 2026. “Meningeal tertiary lymphoid structures; a novel B cell–orchestrated mechanism of neuropathic pain. Invited. Pain Mechanisms and Therapeutics Conference. Florence, IT.
- 2025. Dead cells and dangerous IgG: autoimmune signaling driving neuropathic pain. Invited, CA.
- 2025. Targeting Oxidative Stress Hotspots: A Chemical Strategy for Localized Drug Delivery. Invited, AU.
- 2025. Targeting Neuroimmune Signaling Pathways for Novel Analgesics. Invited, AU.
- 2025. Pain’s Hidden Players: Immune Cells and the Future of Pain Relief. Invited, AU.
- 2025. “Beyond Neurons: Targeting Immune Cells for Persistent Pain Management. Invited, AU.
- 2025. Pain’s Hidden Players: Immune Cells and the Future of Pain Relief. Invited, AU.
- 2025. B cells regulate pain and formation of DRG tertiary lymphoid structures after peripheral nerve injury. Invited. Bordeaux, FR.
- 2025. Regulation of neuropathic pain by B cells. Invited. Oxford, GB.
- 2024. “Neuroimmune mechanisms of neuropathic pain: opportunities for therapeutic intervention”. Invited, BR.
- 2024. Neuroscience School of Advanced Studies. Invited. Venice, IT.
- 2024. B cell regulation of pain after nerve injury. Invited, BR.
- 2024. Engaging the antioxidant transcription factor NRF2 to alleviate neuropathic pain. Invited. Amsterdam, NL.
- 2024. Induction of autoantibodies after peripheral nerve injury. Invited. Amsterdamn, NL.
- 2023. HDAC6 inhibitors as novel drug candidates to reverse chemotherapy-induced mechanical pain. Invited. Lisbon, PT.
- 2023. Exercise prehabilitation and immune regulation in neuropathic pain. Invited. Rehovot, IL.
- 2022. B cell Regulation of Neuropathic Pain”. Invited. Taichung, TW.
- 2022. B cell Regulation of Neuropathic Pain. Invited. Toronto, CA.
- 2021. Opioid-induced neuropathic pain persistence: neuroimmune mechanisms. Invited. Virtual, US.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Changchub, CN.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Guangzhou, CN.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Beijing, CN.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Beijing, CN.
- 2019. Opioid-induced neuropathic pain persistence: neuroimmune mechanisms. Invited. Cairns, AU.
- 2017. “Immune control of pain chronicity and severity”. Invited. Sydney, AU.
- 2017. Immune control of the severity and chronicity of pain. Invited. Melbourne, AU.
- 2017. Neuroimmune crosstalk in neuropathic pain. Invited. PsychoNeuroImmunology Oz Satellite Symposium. Sydney, AU.
- 2017. Neuroimmune crosstalk in neuropathic pain. Invited. Sydney, AU.
- 2017. The how and why of networking for scientists. Invited. Sydney, AU.
- 2016. Neuroimmune signaling: a regulator of the severity and duration of pathological pain. Invited. Centre for Nanoscale BioPhotonics Colloquium. Adelaide, AU.
- 2016. The role of microglia in the transition from acute to chronic pain”, and “Running from pain: exercise as an immunomodulatory therapy. Invited. Sao Paolo, BR.
- 2014. The neuroimmune interface: implications for the transition from acute to chronic pain. Invited. Symposium on “Inflammatory mediators and chronic pain”. Liege, BE.
- 2013. “Repeated morphine enhances peripheral nerve injury-induced allodynia via central immune mechanisms”. Invited. Symposium on “Pain and sickness response”. Stockholm, SE.
- 2010. Role of peripheral immune mechanisms in pain. Invited. Gold Coast, AU.
Formal Peers
- 2022. B cell regulation of neuropathic pain. Invited. Durham, NC, US.
- 2022. Antibody receptor signaling via astrocytes: a new pathway for neuropathic pain. Invited. Cincinnati, OH, US.
- 2022. Neuroimmune mechanisms of neuropathic pain and its relief. Invited. New York City, NY, US.
- 2022. Activating endogenous antioxidant signaling to relieve neuropathic pain. Invited. Philadelphia, PA, US.
- 2021. Targeting Nrf2 to alleviate neuropathic pain. Invited, US.
- 2021. Opioid-induced neuropathic pain persistence: neuroimmune mechanisms. Invited. Online, US.
- 2020. Fcγ receptor signaling and neuropathic pain. Invited. Online, US.
- 2020. Resolution of neuropathic pain and oxidative stress via activation of Nrf2. Invited. Houston, TX, US.
- 2020. Opioids and pain persistence: a role for neuroimmune mechanisms. Invited. Online, US.
- 2020. Neuroimmune interactions in neuropathic pain: emerging mechanisms and therapeutic targets. Invited. Boulder, CO, US.
- 2020. A role for Nrf2 in alleviating neuropathic pain. Invited. Kansas City, KS, US.
- 2020. Targeting Nrf2 to alleviate neuropathic pain. Invited. Dallas, TX, US.
- 2019. Alleviating neuropathic pain and inflammasome activation via Nrf2. Invited. Milwaukee, WI, US.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Changchun, CN.
- 2019. Neuroimmune signaling in pain: opportunities for therapeutic intervention. Invited. Galveston, TX, US.
- 2019. Targeting the neuroimmune interface to treat persistent pain. Invited. Cincinnati, OH, US.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Beijing, CN.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Beijing, CN.
- 2019. Targeting neuroimmune signaling to relieve chronic pain. Invited. Guangzhou, CN.
- 2019. Repurposing The Nrf2 Activator Dimethyl Fumarate (Tecfidera) For Treatment Of Pain Due To Traumatic Nerve Injury In Male Rats. Invited. Orlando, FL, US.
- 2019. Targeting the neuroimmune interface to treat persistent pain. Invited. Austin, TX, US.
- 2018. Targeting the neuroimmune interface to treat persistent pain. Invited. Tuscon, AZ, US.
- 2018. The role of neuroimmune signaling in the transition from acute to chronic pain. Invited. Houston, TX, US.
- 2017. Neuroimmune regulation of pain. Invited. Melbourne, Australia, AU.
- 2016. Neuroimmune signaling: a regulator of the severity and duration of pathological pain. Invited. Adelaide, Australia, AU.
- 2015. The role of microglia in the transition from acute to chronic pain. Invited. St Louis, MO, US.
- 2015. The role of microglia in the transition from acute to chronic pain. Invited. Albuquerque, NM, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Regulation of Peripheral Neuropathic Pain by B Cells |
| Funding Source: | NIH-NINDS |
| Role: | PI |
| ID: | 2R01NS12625 |
| Date: | 2026 - 2029 |
| Title: | Pathology-activated Drugs to Treat Oxidative Stress Underlying Peripheral Neuropathy |
| Funding Source: | DoD Peer Reviewer Medical Research Program |
| Role: | PI |
| Date: | 2025 - 2027 |
| Title: | Dysregulated peripheral and central TIMP-1 signaling promote aberrant nociceptor function |
| Funding Source: | University of Kansas Medical Research Institute |
| Role: | Principal Investigator-MDACC |
| ID: | R01NS128650 |
| Date: | 2024 - 2027 |
| Title: | “Development of Pathology-activated Drugs for Treatment of Neuropathic Pain |
| Funding Source: | NIH- NINDS |
| Role: | PI |
| ID: | UH3 NS127251 |
| Date: | 2024 - 2027 |
| Title: | Understanding NRF2 repression in malignant peripheral nerve sheath tumor (MPNST) growth and pain |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240220 |
| Date: | 2024 - 2028 |
| Title: | Targeting local B cells to prevent chronification of neuropathic pain |
| Funding Source: | DoD CDMRP Peer Reviewed Medical Research Program |
| Role: | PI |
| ID: | HT9425-24-1-0109 |
| Date: | 2024 - 2027 |
| Title: | Tackling cancer therapy-induced central nervous system deficits |
| Funding Source: | Kleberg Foundation |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Targeting endogenous complement regulatory proteins for pain control |
| Funding Source: | University of Colorado |
| Role: | Co-I |
| ID: | R01 NS134505 |
| Date: | 2023 - 2026 |
| Title: | Development and validation of a translational model of painful diabetic peripheral neuropathy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R61 NS133082 |
| Date: | 2023 - 2028 |
| Title: | The evaluation of HDX-769 for therapeutic effects in chemotherapy induced neuropathy and cognitive impairment mouse models |
| Funding Source: | HDAX Therapeutics |
| Role: | PI |
| ID: | AWD00007441 |
| Date: | 2023 - 2027 |
| Title: | Targeting B cells to prevent the transition from acute to chronic neuropathic pain |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | PR221129 |
| Date: | 2022 - 2024 |
| Title: | Development of Pathology-activated Drugs for Treatment of Neuropathic Pain |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | UG3 NS127251-01A1 |
| Date: | 2022 - 2023 |
| Title: | Stabilisation and Slow Release of a New Oxidative Stress Responsive Pain Drug |
| Funding Source: | The University of Adelaide |
| Role: | Principal Investigator-MDACC |
| ID: | 2014145 |
| Date: | 2022 - 2026 |
| Title: | Targeting B cells to prevent chronification of pain after traumatic nerve injury |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-21-CPMRP-IIRA |
| Date: | 2022 - 2026 |
| Title: | Development of Pathology-Activated Prodrugs for Non-Opioid Treatment of Chronic Pain |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | FP00014533 |
| Date: | 2022 - 2027 |
| Title: | Regulation of Peripheral Neuropathic Pain by B Cells |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | 1 R01 NS126252-01 |
| Date: | 2022 - 2027 |
| Title: | Development of Pathology y-activated Drugs for Treatment of Neuropathic Pain |
| Funding Source: | NIH/NINDS |
| Role: | Co-PI |
| ID: | 1 UG3 NS127251 - 01 |
| Date: | 2021 - 2026 |
| Title: | The Neuroimmune Basis of Inflammation-Induced Motivational Anhedonia |
| Funding Source: | NIH/NIMH |
| Role: | Co-I |
| ID: | R01 MH 128997 |
| Date: | 2021 - 2023 |
| Title: | Development of Pathology-Activated Prodrugs for Non-Opioid Treatment of Chronic Pain |
| Funding Source: | The University of Adelaide |
| Role: | Co-I |
| ID: | 1 UG3 NS123936-01 |
| Date: | 2021 - 2022 |
| Title: | Analgesic Mechanisms of Fumarates for Treatment of Post-Surgical Pain |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Identification of Treatments for Chronic Pain Using Peripheral Blood Derived Microglia-like Cells as a Model System |
| Funding Source: | Texas Childrens Hospital |
| Role: | Co-I |
| ID: | R01OD029905 |
| Date: | 2020 - 2025 |
| Title: | Translational Pain Research Training Program |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | FP00008144 |
| Date: | 2020 - 2023 |
| Title: | Astrocyte Fc Gamma Receptor Signaling in Spinal Cord as a Novel Mechanism for Neuropathic Pain |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | FP00008840 |
| Date: | 2020 - 2022 |
| Title: | Nrf2-Dependent Protection of Neurons and Mitochondria by Fumaric Acid Esters |
| Funding Source: | Biogen IDEC |
| Role: | PI |
| ID: | LS2020-0057881 |
| Date: | 2019 - 2022 |
| Title: | Validation of PRDM12 as a Target for Treatment of High Impact Pain |
| Funding Source: | The University of Dallas |
| Role: | Principal Investigator-MDACC |
| Date: | 2019 - 2024 |
| Title: | Nrf2 Activation for Addiction-Free Treatment of Neuropathic Pain |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | 1RF1NS113840 |
| Date: | 2019 - 2022 |
| Title: | Antibody Receptor Signaling via Astrocytes: A New Pathway for Neuropathic Pain |
| Funding Source: | American Pain Society, Rita Allen Foundation |
| Role: | PI |
| ID: | FP7066 |
| Date: | 2019 - 2024 |
| Title: | Targeting Neuroimmune Interactions to Prevent Neuropathic Pain Chronification |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | R01 NS113826 |
| Date: | 2019 - 2024 |
| Title: | The Metabolic Basis of Inflammation-Induced Depression |
| Funding Source: | NIH/NIMH |
| Role: | Co-I |
| ID: | R01MH1219440 |
| Date: | 2019 - 2020 |
| Title: | Development of pathology-activated drugs for non-opioid treatment of chronic pain |
| Funding Source: | International Association for the Study of Pain |
| Role: | PI |
| ID: | FP00007977 |
| Date: | 2019 - 2023 |
| Title: | Fc Gamma Receptor Signaling: A New Pathway for Sustained Neuropathic Pain |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH1910160 |
| Date: | 2019 - 2024 |
| Title: | Discovery and Validation of a Novel P2X7R Ligand as a Predictive Biosignature of Treatment Response in Human Post-Operative Pain |
| Funding Source: | The University of Health Science Center at Houston |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | Discovery and Analytical Validation of Inflammatory Bio-Signatures of the Human Pain Experience |
| Funding Source: | UT Health Science Center Houston |
| Role: | Principal Investigator-MDACC |
| ID: | R01NS113316 |
| Date: | 2019 - 2022 |
| Title: | The Role of Microglia in Depression Co-Morbid with Chronic Pain |
| Funding Source: | Brain and Behavior Research Foundation |
| Role: | PI |
| ID: | 27361 |
| Date: | 2019 - 2019 |
| Title: | Uncovering microglial function in supraspinal brain regions by chemogenetics: implications for the sensory and affective components of neuropathic pain |
| Funding Source: | National Natural Science Foundation of China |
| Role: | PI |
| ID: | N/A |
| Date: | 2018 - 2024 |
| Title: | PQ12 Targeting HDAC6 for Chemotherapy Induced Neuropathy and Chemobrain |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 R01 CA227064 |
| Date: | 2017 - 2020 |
| Title: | Derivation of the Mechanisms Mediating the Adverse Effects of Morphine in a Rodent Model of SCI: Functional Recovery and Neuron Loss |
| Funding Source: | Texas A&M University |
| Role: | Co-I |
| ID: | SC160225 |
| Date: | 2017 - 2019 |
| Title: | Fc gammaR-signaling mechanisms underlying chemotherapy-induced neurpathic pain |
| Funding Source: | Institutional Research Grant Program |
| Role: | PI |
| ID: | N/A |
| Date: | 2017 - 2021 |
| Title: | Rescuing Our Warriors from Chronic Pain: A Battlefield-to-Nondeployment Means to Prevent Opioid-induced Amplification of Neuropathic Pain from Traumatic Injury |
| Funding Source: | University of Colorado |
| Role: | Principal Investigator-MDACC |
| ID: | W81XWH-16-1-0161 |
| Date: | 2017 - 2020 |
| Title: | Rising STARs Award |
| Funding Source: | University of Texas System |
| Role: | PI |
| Date: | 2016 - 2023 |
| Title: | Targeting Neuropathic Pain Prevention: Modulating the Neuroimmunology of Peripheral Nerve Injury |
| Funding Source: | University of Colorado |
| Role: | Principal Investigator-MDACC |
| ID: | R01AT009366 |
| Date: | 2016 - 2021 |
| Title: | Start-up Funds |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | Identification of Causes and Treatments for Chronic Pain in a Model of Gulf War Illness |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH1910161 |
| Date: | 2016 - 2024 |
| Title: | Astrocyte Neuroimmunology after Sciatic Nerve Injury: A Role of Fc Gamma Receptors |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | R01 NS113826 |
| Date: | 2014 - 2016 |
| Title: | Exacerbation of neuropathic pain by opioids: a role for TLR4 and inflammasomes |
| Funding Source: | American Pain Society Future Leaders in Pain Research Grant |
| Role: | PI |
| Date: | 2012 - 2016 |
| Title: | XT-101 for Treatment of MS-Related Symptoms |
| Funding Source: | National Multiple Sclerosis Society |
| Role: | Co-PI |
| Title: | Exploiting Diurnal Immune Cell Variations to Promote Cognitive Function |
| Funding Source: | Australian Research Council |
| Role: | Principal Investigator-MDACC |
| ID: | DP220101964 |
Selected Publications
Peer-Reviewed Articles
- Grace PM, Pandey VK, Acharya TK, Willcox KF, Dembla S, Ramanujan A, Grieco AR, Zuberi YA, Mahalingam R, Shepherd AJ, Heijnen CJ. Peripheral nerve injury reduces macrophage efferocytosis to facilitate neuropathic pain. Proc Natl Acad Sci U S A 123(1), 2026. e-Pub 2026. PMID: 41481465.
- 1.Cazuza CA, Laoumtzis M, Zagrai SM,, Lacagnina MJ, Grieco AR, Morphett JC, Hutchinson MR, Grace PM. Brain-wide changes in microglial morphology following peripheral nerve injury. J Pain, 2026. PMID: 41109469.
- Hodges PW, Fiore NT, Watkins LR, Klyne DM, Coppieters MW, Grace PM. Pain and the immune system. Musculoskelet Sci Pract . e-Pub 2026. PMID: 41622089.
- Stachura DL, Rivera-Escalera F, Turner DJL, Rasheed MSU, Ruiz D, Avery TA, Davalos A, Herr RJ, Grace PM, Abell A. Structure-property relationship analysis of α-keto ester prodrugs of monomethyl fumarate as NRF2 activators. ACS Chem Neurosci. e-Pub 2026.
- Ganji-Angirekula S, Segada NW, Grace PM, Hasan P, Wang J, Sun X, Javed S. Prevalence of PD-1 Inhibitor-Associated Peripheral Neuropathy: A Retrospective Cohort Study. Life (Basel) 16(1):31, 2025. e-Pub 2025. PMID: 41598188.
- Grace PM, Watkins LR. Reordering neuroimmune signaling to prevent and resolve chronic pain. PAIN, 2025. e-Pub 2025. PMID: 41086322.
- Singh, A, Ruiz, DM, Pandey, VK, Ur Rasheed, MS, Turner, DJ, Avery, TD, Abell, AD, Grace, P. Targeted activation of Nrf2 at sites of oxidative stress reverses doxorubicin-induced cognitive impairments in mice. Brain, behavior, and immunity 129:547-556, 2025. e-Pub 2025. PMID: 40592417.
- Avery TD, Li J, Turner DJL, Rasheed MSU, Cherry FR, Stachura DL, Rivera-Escalera F, Ruiz DM, Lacagnina MJ, Gaffney CM, Aguilar C, Yu J, Wang Y, Xie H, Liang D,, Shepherd AJ,, Abell AD,, Grace PM. Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders. Nat Biotechnol, 2025. e-Pub 2025. PMID: 39496929.
- Lacagnina MJ, Willcox KF, Fiore NT, Grieco AR, Li J, Heijnen CJ, Grace PM. Fc gamma receptor IIa signaling from spinal cord astrocytes promotes neuropathic pain. J PAIN, 2025. e-Pub 2025. PMID: 40945637.
- Acharya TK, Pan Y, Grace PM, Heijnen CJ, Mahalingam R.. Deciphering transcriptomic changes in chemobrain: a comprehensive review. Acta Neuropathol Commun, 2025. e-Pub 2025. PMID: 40886025.
- Singh, AK, Bernabucci, M, Dvorak, NM, Haghighijoo, Z, Di Re, J, Goode, N, Kadakia, FK, Maile, LA, Folorunso, OO, Wadsworth, PA, Tapia, CM, Wang, P, Wang, J, Chen, H, Xue, Y, Singh, J, Hankerd, KM, Gamez, IJ, Kager, M, Truong, V, Walsh, P, Shiers, S, Kuttanna, N, Liao, H, Marchi, M, Salvi, E, D’Amato, I, D’Amico, D, Arman, P, Faber, CG, Malik, RA, de Tommaso, M, Ziegler, D, Rajarathnam, K, Green, TA, Grace, P, Sapio, MR, Iadarola, MJ, Cuny, GD, Chow, DS, Pinter, GL, Davidson, S, Green, DP, La, JH, Chung, JM, Zhou, J, Price, TJ, Salisbury, E, Yuan, S, Laezza, F. Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models. Journal of Clinical Investigation 135(14), 2025. e-Pub 2025. PMID: 40662354.
- Mohammadian M, Efthimiou N, Brusaferri L, Cooper-Hohn J, Kim M, Murphy JP, Alshelh Z, Grmek G, Schnieders JH, Chane CA, Carmichael TG, Yang D, Schubert JJ, Turkheimer FE, Grace PM, Catana C, Stufflebeam SM, Edwards RR, Napadow V, Sullivan K, Nahrendorf M, Gilman JM, Loggia ML. Evidence for a role of skull bone marrow in human chronic pain as revealed by TSPO PET imaging. medRxiv. e-Pub 2025. PMID: 41551382.
- Yousuf, MS, Moreno, MM, Woodall, BJ, Thakur, V, Li, J, He, L, Arjarapu, R, Royer, D, Zhang, J, Chattopadhyay, M, Grace, P, Price, TJ. Diroximel Fumarate Acts Through Nrf2 to Attenuate Methylglyoxal-Induced Nociception in Mice and Decrease ISR Activation in DRG Neurons. Diabetes 74(5):827-837, 2025. e-Pub 2025. PMID: 39976640.
- Fiore, N, Willcox, KF, Dayani, D, Zuberi, YA, Heijnen, CJ, Grace, P. Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain. Brain, behavior, and immunity 125:371-387, 2025. e-Pub 2025. PMID: 39870199.
- Cazuza, RA, Zagrai, SM, Grieco, AR, Avery, TD, Abell, AD, Wey, HY, Loggia, ML, Grace, P. Translocator protein 18 kDa (TSPO) is upregulated in rat brain after peripheral nerve injury and downregulated by diroximel fumarate. Brain, behavior, and immunity 123:11-27, 2025. e-Pub 2025. PMID: 39218234.
- Stachura D, Rivera-Escalera F, Turner D, Rasheed M, Ruiz D, Avery T, Grace PM, Herr J, Davalos A, Abell A. Structure-Property Relationship Analysis of α-Keto Ester Prodrugs of Monomethyl Fumarate as NRF2 Activators. ChemRxiv. 2025, 2025.
- Fiore NT, Willcox KF, Grieco AR, Dayani D, Zuberi YA, Heijnen CJ, Grace PM. Autoreactive IgG levels and Fc receptor γ subunit upregulation drive mechanical allodynia after nerve constriction or crush injury. Pain, 2025. e-Pub 2025. PMID: 40728528.
- Grace PM, Willcox KF, Grieco AR, Dayani D, Zuberi YA, Heijnen CJ, Grace PM. Autoreactive IgG levels and Fc receptor γ subunit upregulation drive mechanical allodynia after nerve constriction or crush injury. bioRxiv, 2025.
- Das, AC, Nichols, JM, Crelli, CV, Liu, L, Vichare, R, Pham, HV, Gaffney, CM, Cherry, FR, Grace, P, Shepherd, AJ, Janjic, JM. Injectable, reversibly thermoresponsive captopril-laden hydrogel for the local treatment of sensory loss in diabetic neuropathy. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 39152212.
- Lacagnina, MJ, Willcox, KF, Boukelmoune, N, Bavencoffe, AG, Sankaranarayanan, I, Barratt, DT, Zuberi, YA, Dayani, D, Chavez, MV, Lu, JT, Farinotti, AB, Shiers, S, Barry, AM, Mwirigi, JM, Tavares-Ferreira, D, Funk, GA, Cervantes, AM, Svensson, CI, Walters, E, Hutchinson, MR, Heijnen, CJ, Price, TJ, Fiore, N, Grace, P. B cells drive neuropathic pain–related behaviors in mice through IgG–Fc gamma receptor signaling. Science translational medicine 16(766), 2024. e-Pub 2024. PMID: 39321269.
- Green-Fulgham, SM, Lacagnina, MJ, Willcox, KF, Li, J, Harland, ME, Ciena, AP, Rocha, IR, Ball, JB, Dreher, RA, Zuberi, YA, Dragavon, JM, Chacur, M, Maier, SF, Watkins, LR, Grace, P. Voluntary wheel running prevents formation of membrane attack complexes and myelin degradation after peripheral nerve injury. Brain, behavior, and immunity 115:419-431, 2024. e-Pub 2024. PMID: 37924957.
- Green-Fulgham, SM, Ball, JB, Kwilasz, AJ, Harland, ME, Frank, MG, Dragavon, JM, Grace, P, Watkins, LR. Interleukin-1beta and inflammasome expression in spinal cord following chronic constriction injury in male and female rats. Brain, behavior, and immunity 115:157-168, 2024. e-Pub 2024. PMID: 37838078.
- Green-Fulgham SM, Lacagnina MJ, Wilcox KF, Li J, Harland ME, Polican Ciena A, Correia Rocha IR, Ball JB, Dreher RA, Zuberi YA, Dragavon J, Chacur M, Maier SF, Watkins LR, Grace PM. Voluntary wheel running prevents formation of membrane attack complexes and myelin degradation after peripheral nerve injury. Brain Behav Immun:115:419-31, 2024. e-Pub 2024. PMID: 37924957.
- Moreno MM, Payne C, Mazhar K, Arendt-Tranholm A, Yap N, Chiu AP, Wilde MA, Patel PJ, Yousuf MS, Taveres-Ferreira D, Jarvik JG, Turner JA, Grace PM. IGHG4 Expression in C2 Human Dorsal Root Ganglion Potentially Links B Cells to Spreading Chronic Neck Pain. medRxiv, 2024.
- Singh AK, Avery TD, Turner DJL, Abell AD, Grace PM. Systemic and targeted activation of Nrf2 reverses doxorubicin-induced cognitive and sensorimotor deficits in mice. bioRxiv, 2024.
- Yousuf MS, Mancilla-Moreno M, Li J, He L, Royer D, Zhang J, Woodall BJ, Grace PM, Price TJ. Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice decreases ISR activation in DRG neurons. bioRxiv, 2023.
- Li J, Stratton HJ, Lorca SA, Grace PM, Khanna R. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats. Channels (Austin) 16(1):1-8, 2022. e-Pub 2022. PMID: 34983286.
- Zhang J, Junigan JM, Trinh R, Kavelaars A, Heijnen CJ, Grace PM. HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling. J Neurosci 42(42):7862-7874, 2022. e-Pub 2022. PMID: 36096670.
- Green-Fulgham SM, Harland ME, Ball JB, Li J, Lacagnina MJ, D'Angelo H, Dreher RA, Willcox KF, Lorca SA, Kwilasz AJ, Maier SF, Watkins LR, Grace PM. Preconditioning by voluntary wheel running attenuates later neuropathic pain via nuclear factor E2-related factor 2 antioxidant signaling in rats. Pain 163(10):1939-1951, 2022. e-Pub 2022. PMID: 35486864.
- Green-Fulgham SM, Ball JB, Maier SF, Rice KC, Watkins LR, Grace PM. Suppression of active phase voluntary wheel running in male rats by unilateral chronic constriction injury: Enduring therapeutic effects of a brief treatment of morphine combined with TLR4 or P2X7 antagonists. J Neurosci Res 100(1):265-277, 2022. e-Pub 2020. PMID: 32533604.
- Green-Fulgham SM, Harland ME, Ball JB, D'Angelo H, Dreher RA, Li J Lacagnina MJ, Lorca SA, Kwilasz AJ, Maier SF, Watkins LR, Grace PM. Preconditioning by voluntary wheel running attenuates later neuropathic pain via Nrf2 antioxidant signaling in rats. bioRxiv, 2021. e-Pub 2021.
- Cata JP, Patiño M, Lacagnina MJ, Li J, Gorur A, Agudelo-Jimenez R, Wei B, Hagberg CA, Dougherty PM, Shureiqi I, Yang P, Grace PM. A rat model to investigate quality of recovery after abdominal surgery. Pain Rep 6(2):e943, 2021. e-Pub 2021. PMID: 34235345.
- Muscat SM, Deems NP, D'Angelo H, Kitt MM, Grace PM, Andersen ND, Silverman SN, Rice KC, Watkins LR, Maier SF, Barrientos RM. Postoperative cognitive dysfunction is made persistent with morphine treatment in aged rats. Neurobiol Aging 98:214-224, 2021. e-Pub 2021. PMID: 33341652.
- Grace PM, Tawfik VL, Svensson CI, Burton MD, Loggia ML, Hutchinson MR. The Neuroimmunology of Chronic Pain: From Rodents to Humans. J Neurosci 41(5):855-865, 2021. e-Pub 2021. PMID: 33239404.
- Lacagnina MJ, Li J, Lorca S, Rice KC, Sullivan K, O'Callaghan JP, Grace PM. A role for neuroimmune signaling in a rat model of Gulf War Illness-related pain. Brain Behav Immun 91:418-428, 2021. e-Pub 2021. PMID: 33127584.
- Mai CL, Tan Z, Xu YN, Zhang JJ, Huang ZH, Wang D, Zhang H, Gui WS, Zhang J, Lin ZJ, Meng YT, Wei X, Jie YT, Grace PM, Wu LJ, Zhou LJ, Liu XG. CXCL12-mediated monocyte transmigration into brain perivascular space leads to neuroinflammation and memory deficit in neuropathic pain. Theranostics 11(3):1059-1078, 2021. e-Pub 2021. PMID: 33391521.
- Avery TD, Li J, Turner DJL, Cherry FR, Ur Rasheed MS, Aguilar C, Shepherd AJ, Yu J, Grace PM, Abell AD. Drug targeting to sites of oxidative stress using the Baeyer-Villiger reaction. bioRxiv, 2021.
- Green-Fulgham SM, Harland ME, Ball JB, D’Angelo H, Dreher RA, Li J, Lacagnina MJ, Lorca SA, Kwilasz AJ, Maier SF, Watkins LR, Grace PM. Preconditioning by voluntary wheel running attenuates later neuropathic pain via Nrf2 antioxidant signaling in rats. bioRxiv, 2021.
- Lacagnina MJ, Heijnen CJ, Watkins LR, Grace PM. Autoimmune regulation of chronic pain. Pain Rep 6(1):e905, 2021. e-Pub 2021. PMID: 33981931.
- Doyle TM, Janes K, Chen Z, Grace PM, Esposito E, Cuzzocrea S, Largent-Milnes TM, Neumann WL, Watkins LR, Spiegel S, Vanderah TW, Salvemini D. Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents. Pain 161(9):2107-2118, 2020. e-Pub 2020. PMID: 32301840.
- Li J, Ma J, Lacagnina MJ, Lorca S, Odem MA, Walters ET, Kavelaars A, Grace PM. Oral Dimethyl Fumarate Reduces Peripheral Neuropathic Pain in Rodents via NFE2L2 Antioxidant Signaling. Anesthesiology 132(2):343-356, 2020. e-Pub 2020. PMID: 31939850.
- Odem MA, Lacagnina MJ, Katzen SL, Li J, Spence EA, Grace PM, Walters ET. Sham surgeries for central and peripheral neural injuries persistently enhance pain-avoidance behavior as revealed by an operant conflict test. Pain 160(11):2440-2455, 2019. e-Pub 2019. PMID: 31323014.
- Green-Fulgham SM, Ball JB, Kwilasz AJ, Fabisiak T, Maier SF, Watkins LR, Grace PM. Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats. Pain 160(11):2634-2640, 2019. e-Pub 2019. PMID: 31299018.
- Peng Y, Zhang X, Zhang T, Grace PM, Li H, Wang Y, Li H, Chen H, Watkins LR, Hutchinson MR, Yin H, Wang X. Lovastatin inhibits Toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain. Brain Behav Immun 82:432-444, 2019. e-Pub 2019. PMID: 31542403.
- Zhang X, Peng Y, Grace PM, Metcalf MD, Kwilasz AJ, Wang Y, Zhang T, Wu S, Selfridge BR, Portoghese PS, Rice KC, Watkins LR, Hutchinson MR, Wang X. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling. FASEB J 33(8):9577-9587, 2019. e-Pub 2019. PMID: 31162938.
- Grace PM, Galer EL, Strand KA, Corrigan K, Berkelhammer D, Maier SF, Watkins LR. Repeated morphine prolongs postoperative pain in male rats. Anesth Analg 128(1):161-167, 2019. e-Pub 2019. PMID: 29596097.
- Grace PM, Strand KA, Galer EL, Rice KC, Maier SF, Watkins LR. Protraction of neuropathic pain by morphine is mediated by spinal damage associated molecular patterns (DAMPs) in male rats. Brain Behav Immun 72:45-50, 2018. e-Pub 2018. PMID: 28860068.
- Grace PM, Strand KA, Galer EL, Maier SF, Watkins LR. MicroRNA-124 and microRNA-146a both attenuate persistent neuropathic pain induced by morphine in male rats. Brain Res 1692:9-11, 2018. e-Pub 2018. PMID: 29723521.
- Grace PM, Wang X, Strand KA, Baratta MV, Zhang Y, Galer EL, Yin H, Maier SF, Watkins LR. DREADDed microglia in pain: implications for spinal inflammatory signaling in male rats. Exp Neurol 304:125-31, 2018. e-Pub 2018. PMID: 29530713.
- Lacagnina MJ, Kopec AM, Cox SS, Hanamsagar R, Wells C, Slade S, Grace PM, Watkins LR, Levin ED, Bilbo SD. Early-life experience alters opioid self-administration in adulthood via anti-inflammatory IL-10 signaling in nucleus accumbens. Neuropsychopharmacology 42(11):2128-40, 2017. e-Pub 2017. PMID: 28436446.
- Lewis SS, Grace PM, Hutchinson MR, Maier SF, Watkins LR. Constriction of the motor facial nerve produces unilateral craniofacial allodynia. Brain Behav Immun 64:59-64, 2017. e-Pub 2017. PMID: 27993689.
- Grace PM, Loram LC, Christianson JP, Strand KA, Flyer-Adams JG, Penzkover KR, Forsayeth JR, van Dam AM, Mahoney MJ, Maier SF, Chavez RA, Watkins LR. Behavioral assessment of pain, fatigue, and mood disorders in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy. Brain Behav Immun 59:49-54, 2017. e-Pub 2017. PMID: 27189037.
- Ellis A, Grace PM, Wieseler J, Favret J, Springer K, Skarda B, Ayala M, Hutchinson MR, Falci S, Rice KC, Maier SF, Watkins LR. Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain Behav Immun 58:348-356, 2016. e-Pub 2016. PMID: 27519154.
- Das N, Dewan V, Grace PM, Gunn RJ, Tamura R, Tzarum N, Watkins LR, Wilson IA, Yin H. HMGB1 activates proinflammatory signaling via TLR5 leading to allodynia. Cell Rep 17(4):1128-1140, 2016. e-Pub 2016. PMID: 27760316.
- Grace PM, Fabisiak TJ, Green-Fulgham SM, Anderson ND, Strand KA, Kwilasz AJ, Galer EL, Walker FR, Greenwood BN, Maier SF, Fleshner M, Watkins LR. Prior voluntary wheel running attenuates neuropathic pain. Pain 157(9):2012-23, 2016. e-Pub 2016. PMID: 27355182.
- Grace PM, Strand KA, Galer EL, Urban DJ, Wang X, Baratta MV, Fabisiak TJ, Anderson ND, Cheng K, Greene LI, Berkelhammer D, Zhang Y, Ellis AL, Yin HH, Campeau S, Rice KC, Roth BL, Maier SF, Watkins LR. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A 113(24):E3441-50, 2016. e-Pub 2016. PMID: 27247388.
- Grace PM, Shimizu K, Strand KA, Rice KC, Deng G, Watkins LR, Herson PS. (+)-Naltrexone is neuroprotective and promotes alternative activation in the mouse hippocampus after cardiac arrest/cardiopulmonary resuscitation. Brain Behav Immun 48:115-22, 2015. e-Pub 2015. PMID: 25774010.
- Selfridge BR, Wang X, Zhang Y, Yin H, Grace PM, Watkins LR, Jacobson AE, Rice KC. Structure-Activity Relationships of (+)-Naltrexone-Inspired Toll-like Receptor 4 (TLR4) Antagonists. J Med Chem 58(12):5038-52, 2015. e-Pub 2015. PMID: 26010811.
- Galer EL, Grace PM. Reactive aldehydes: a new player in inflammatory pain. Ann Transl Med 3(Suppl 1):S23, 2015. e-Pub 2015. PMID: 26046069.
- Griggs RB, Donahue RR, Morgenweck J, Grace PM, Sutton A, Watkins LR, Taylor BK. Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARγ mechanisms. Pain 156(3):469-82, 2015. e-Pub 2015. PMID: 25599238.
- Grace PM, Ramos KM, Rodgers KM, Wang X, Hutchinson MR, Lewis MT, Morgan KN, Kroll JL, Taylor FR, Strand KA, Zhang Y, Berkelhammer D, Huey MG, Greene LI, Cochran TA, Yin H, Barth DS, Johnson KW, Rice KC, Maier SF, Watkins LR. Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae. Neuroscience 280:299-317, 2014. e-Pub 2014. PMID: 25241065.
- Narayan DS, Casson RJ, Ebneter A, Chidlow G, Grace PM, Hutchinson MR, Wood JP. Immune priming and experimental glaucoma: the effect of prior systemic lipopolysaccharide challenge on tissue outcomes after optic nerve injury. Clin Exp Ophthalmol 42(6):539-54, 2014. e-Pub 2014. PMID: 24373007.
- Grace PM, Strand KA, Maier SF, Watkins LR. Suppression of voluntary wheel running in rats is dependent on the site of inflammation: evidence for voluntary running as a measure of hind paw-evoked pain. J Pain 15(2):121-8, 2014. e-Pub 2014. PMID: 24287315.
- Nicotra L, Tuke J, Grace PM, Rolan PE, Hutchinson MR. Sex differences in mechanical allodynia: how can it be preclinically quantified and analyzed?. Front Behav Neurosci 8:40, 2014. e-Pub 2014. PMID: 24592221.
- Wang X, Grace PM, Pham MN, Cheng K, Strand KA, Smith C, Li J, Watkins LR, Yin H. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain. FASEB J 27(7):2713-22, 2013. e-Pub 2013. PMID: 23568774.
- Kwok YH, Tuke J, Nicotra LL, Grace PM, Rolan PE, Hutchinson MR. TLR 2 and 4 responsiveness from isolated peripheral blood mononuclear cells from rats and humans as potential chronic pain biomarkers. PLoS One 8(10):e77799, 2013. e-Pub 2013. PMID: 24204973.
- Loram LC, Grace PM, Strand KA, Taylor FR, Ellis A, Berkelhammer D, Bowlin M, Skarda B, Maier SF, Watkins LR. Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy. Brain Behav Immun 26(8):1256-64, 2012. e-Pub 2012. PMID: 22902523.
- Grace PM, Hurley D, Barratt DT, Tsykin A, Watkins LR, Rolan PE, Hutchinson MR. Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model. J Neurochem 122(5):976-94, 2012. e-Pub 2012. PMID: 22697386.
- Grace PM, Hutchinson MR, Bishop A, Somogyi AA, Mayrhofer G, Rolan PE. Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. Brain Behav Immun 25(3):503-13, 2011. e-Pub 2011. PMID: 21134441.
- Grace PM, Stanford T, Gentgall M, Rolan PE. Utility of saccadic eye movement analysis as an objective biomarker to detect the sedative interaction between opioids and sleep deprivation in opioid-naive and opioid-tolerant populations. J Psychopharmacol 24(11):1631-40, 2010. e-Pub 2010. PMID: 20142307.
- Grace PM, Hutchinson MR, Manavis J, Somogyi AA, Rolan PE. A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity. J Neurosci Methods 193(1):47-53, 2010. e-Pub 2010. PMID: 20817038.
- Pandey V, Acharya TK, Willcox KF, Dembla S, Ramanujan A, Grieco AR, Zuberi YA, Mahalingam R, Shepherd AJ, Heijnen CJ, Grace PM. Impaired macrophage efferocytosis following peripheral nerve injury facilitates neuropathic pain.
- Acharya TK, Pandey VK, Willcox KF, Lucena-Silva GV, Lacagnina MJ, Singhmar P, Zuberi YA, Ruiz DM, Cunha TM, Heijnen CJ, Grace PM. DRG meningeal tertiary lymphoid structures are regulated by B cells as a pronociceptive locus after peripheral nerve injury.
- Gaffney CM, Casaril AM, Mahmud I, Wei B, Jiang Y, Fiore NT, Valadez KM, Kolb EA, Cherry FR, Shi L, Dunner K, Lorenzi PL, Reiken SR, Grace PM, Mahalingam R, Guise TA, Hodo CL, Shepherd AJ. Inflammatory neuropathy in mouse and primate models of colorectal cancer.
Review Articles
- Mustafa S, Bajic JE, Barry B, Evans S, Siemens KR, Hutchinson MR, Grace PM. One immune system plays many parts: The dynamic role of the immune system in chronic pain and opioid pharmacology. Neuropharmacology 228:109459, 2023. e-Pub 2023. PMID: 36775098.
- Hoogendoorn A, Avery TD, Li J, Bursill C, Abell A, Grace PM. Emerging Therapeutic Applications for Fumarates. Trends Pharmacol Sci 42(4):239-254, 2021. e-Pub 2021. PMID: 33618840.
- Lacagnina MJ, Watkins LR, Grace PM. Toll-like receptors and their role in persistent pain. Pharmacol Ther 184:145-58, 2018. e-Pub 2018. PMID: 28987324.
- Grace PM, Gaudet AD, Staikopoulos V, Maier SF, Hutchinson MR, Salvemini D, Watkins LR. Nitroxidative Signaling Mechanisms in Pathological Pain. Trends Neurosci 39(12):862-879, 2016. e-Pub 2016. PMID: 27842920.
- Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune response. Cell Mol Life Sci 73(22):4249-4264, 2016. e-Pub 2016. PMID: 27314883.
- Dodds KN, Beckett EA, Evans SF, Grace PM, Watkins LR, Hutchinson MR. Glial contributions to visceral pain: implications for disease etiology and the female predominance of persistent pain. Transl Psychiatry 6(9):e888, 2016. e-Pub 2016. PMID: 27622932.
- Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 96(Pt A):55-69, 2015. e-Pub 2015. PMID: 25446571.
- Grace PM, Maier SF, Watkins LR. Opioid-induced central immune signaling: implications for opioid analgesia. Headache 55(4):475-89, 2015. e-Pub 2015. PMID: 25833219.
- Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol 14(4):217-31, 2014. e-Pub 2014. PMID: 24577438.
- Grace PM, Rolan PE, Hutchinson MR. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain Behav Immun 25(7):1322-32, 2011. e-Pub 2011. PMID: 21496480.
- Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 63(3):772-810, 2011. e-Pub 2011. PMID: 21752874.
Other Articles
- Iyer, H, Benoist, C, Bilbo, SD, Boulanger, LM, Burton, MD, Daniels, BP, Deczkowska, A, Flajnik, MF, Gareau, MG, Grace, P, Irazoqui, JE, Rosi, S, Salinas, I, Schaefer, A, Sokol, CL, Williams, DW, Klein, RS Systems neuroimmunology. Nature Immunology 26(3):325-329, 2025. PMID: 39939753.
- Grace PM, Pigatto GR, Lucena-Silva GV, Gonçalves WA, Quadros AU, Damasceno S, A Silva CE, Hovhannisyan V, Acharya TK, Nascimento DC, Jager SE, Meschick CG, Cavallini MC, Mesquita JP, R Goldstein GN, Dourson AJ, Nakaya HI, F Hockley JR, Ellson CD, Nogueira-Barbosa MH, Freitas GP, Beloti MM, Antunes MM, Menezes GB, Sankaranarayanan I, Mazhar K, Emery EC, Madsen KL, Alves-Filho JC, Cunha FQ, Molofsky AB, Molofsky AV, Price TJ, Smith JE, Grace PM, Becher B, Khoutorsky A, Cunha TM GM-CSF instructs vertebral emergency myelopoiesis in neuropathic pain. bioRxiv.
Editorials
- Grace PM. A backbone for reverse-translation: Evidence for neuroinflammation in patients with low back pain. Brain Behav Immun 75:8-9, 2019. PMID: 30414443.
- Galer EL, Grace PM. Reactice aldehydes: A new player in inflammatory pain. Ann Transl Med Suppl 1(S23), 2015.
- Grace PM. The anatomical distribution of trigeminal neuralgia: a perspective and future directions. Anesth Pain Med 1(3):212-3, 2012. PMID: 24904801.
Abstracts
- Zuberi YA, Lacagnina MJ, Wilcox KF, Junigan JM, Grace PM. Accumulation of immunoglobulin G in dorsal root ganglia and spinal cord after peripheral nerve injury. Gulf Coast Consortium.
- Grace PM, Rolan PE, Farquharson AL. Can ultra-low dose naltrexone reverse opioid-induced hyperalgesia?. Proceedings of the Australian Health and Medical Research Congress.
- Grace PM, Rolan PE, White JM, Hutchinson MR, Somogyi AA. Biomarkers of sedation. Proceedings of the Australian Health and Medical Research Congress.
- Grace PM, Hutchinson MR, Mayrhofer G, Somogyi AA, Rolan PE. Biomarkers of pain. Program No. 458.2/AA23 2009 Neuroscience Meeting Planner. Society for Neuroscience.
- Grace PM, Hutchinson MR, Mayrhofer G, Somogyi AA, Rolan PE. Enhanced neuropathic pain by passive immune transfer using a novel model of graded neuropathy. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Annual Scientific Meeting.
- Grace PM, Hutchinson MR, Mayrhofer G, Somogyi AA, Rolan PE. Enhanced neuropathic pain by passive immune transfer using a novel model of graded neuropathy. Proceedings of the Australian Pain Society.
- Grace PM, Stanford T, Gentgall M, Rolan PE. Objective assessment of the sedative interaction between opioids and sleep deprivation. Proceedings of the Australian Pain Society.
- Grace PM, Rolan PE Hutchinson MR. Harnessing pain heterogeneity and RNA transcriptome to explore mechanisms of chronic pain. Proceedings of the Psychoneuroimmunology Research Society.
- Grace PM, Rolan PE, Hutchinson MR. Novel mechanisms of chronic pain: candidates identified by harnessing pain heterogeneity and RNA transcriptome. Society for Neuroscience.
- Narayan D, Wood J, Ebneter A, Chidlow G, Grace PM, Hutchinson MR, Casson R. Immune priming and experimental glaucoma: The effect of prior systemic lipopolysaccharide challenge on tissue outcomes after optic nerve injury. Proceedings of The Royal Australian and New Zealand College of Ophthalmologists.
- Grace PM, Hurley D, Barratt DT, Watkins LR, Rolan PE Hutchinson MR. Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a correlational study in a graded chronic constriction injury model. Proceedings of the International Behavioral and Neural Genetics Society.
- Grace PM, Hurley D, Barratt DT, Watkins LR, Rolan PE Hutchinson MR. Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a correlational study in a graded chronic constriction injury model. Proceedings of the International Association for the Study of Pain.
- Greene LI, Grace PM, Ramos KM, Huey MG, Strand KA, Maier SF, Watkins LR. The effect of repeated morphine on allodynia and central immune activation following mild peripheral nerve constriction. Society for Neuroscience.
- Skarda BD, Grace PM, Strand KA, Ellis AL, Maier SF, Watkins LR. Prior central immune sensitization potentiates allodynia in response to laparotomy and mild chronic constriction injury: a role for exaggerated neuroinflammation. Society for Neuroscience.
- Grace PM, Loram LC, Strand KA, Christianson JP, Flyer JG, Penzkover KR, Zhang Y, Maier SF, Mahoney MJ Watkins LR. IL-10 gene therapy attenuated multiple sclerosis-like symptoms in a rat model of experimental autoimmune encephalomyelitis (EAE). Society for Neuroscience.
- Grace PM, Greene LI, Strand KA, Rice KC, Maier SF, Watkins LR. Repeated morphine enhances peripheral nerve injury-induced allodynia via central immune mechanisms. Proceedings of the Psychoneuroimmunology Research Society.
- Galer EL, Grace PM, Strand KA, Corrigan K, Berkelhammer D, Skarda B, Rice KC, Maier SF, Watkins LR. Perioperative morphine administration prolongs post-operative pain: a role for TLR4 and inflammasome signaling. Society for Neuroscience.
- Grace PM, Greene LI, Strand KA, Galer EL, Rice KC, Maier SF, Watkins LR. Repeated morphine enhances peripheral nerve injury-induced allodynia via TLR4 and P2X7 in the lumbar spinal cord. Society for Neuroscience.
- Grace PM, Strand KA, Galer EL, Zhang Y, Greene LI, Rice KC, Maier SF, Watkins LR. Therapeutic morphine prolongs neuropathic pain in Fischer 344 rats: a role for TLR4 and inflammasome signaling in the lumbar spinal cord. American Pain Society.
- Grace PM, Strand KA, Galer EL, Zhang Y, Berkelhammer D, Greene LI, Rice KC, Maier SF, Watkins LR. Therapeutic morphine prolongs neuropathic pain in rats: a role for TLR4 and inflammasome signaling in the lumbar spinal cord. Proceedings of the Psychoneuroimmunology Research Society.
- Grace PM, Strand KA, Galer EL, Zhang Y, Greene LI, Rice KC, Maier SF, Watkins LR. Therapeutic morphine prolongs neuropathic pain in Fischer 344 rats: a role for TLR4 and inflammasome signaling in the lumbar spinal cord. Keystone Symposia. The Brain: Adaptation and Maladaptation in Chronic Pain.
- Grace PM, Strand KA, Galer EL, Zhang Y, Berkelhammer D, Greene LI, Rice KC, Maier SF, Watkins LR. Therapeutic morphine prolongs neuropathic pain in rats: a role for TLR4 and inflammasome signaling in the lumbar spinal cord. Society for Neuroscience.
- Grace PM, Strand KA, Galer EL, Zhang Y, Berkelhammer D, Greene LI, Rice KC, Maier SF, Watkins LR. Therapeutic morphine prolongs neuropathic pain in rats: a role for TLR4 and inflammasome signaling in the lumbar spinal cord. Front Range Neuroscience Group Meeting.
- Grace PM, Wang X, Urban DJ, Baratta MV, Galer EL, Strand KA, Zhang Y, Yin H, Roth BL, Maier SF, Watkins LR. Selective manipulation of spinal microglia by chemogenetics: implications for allodynia and inflammatory signaling. American Pain Society.
- Grace PM, Wang X, Urban DJ, Baratta MV, Galer EL, Strand KA, Zhang Y, Yin H, Roth BL, Maier SF, Watkins LR. Selective manipulation of spinal microglia by chemogenetics: implications for allodynia and inflammatory signaling. Proceedings of the Psychoneuroimmunology Research Society.
- Grace PM, Wang X, Urban DJ, Baratta MV, Galer EL, Strand KA, Zhang Y, Yin H, Roth BL, Maier SF, Watkins LR. Selective manipulation of spinal microglia by chemogenetics: implications for allodynia and inflammatory signaling. Society for Neuroscience.
- Grace PM, Strand KA, Galer EG, Anderson N, Fabisiak TJ, Green Fulgham SM, Greenwood BN, Fleshner M, Maier SF, Watkins LR. Prior voluntary wheel running is protective for neuropathic pain. American Pain Society.
- Fabisiak TJ, Lacagnina MJ, Grace PM. Mapping microglial reactivity in the brain after sciatic nerve injury. Proceedings of the Psychoneuroimmunology Research Society.
- Lacagnina MJ, Fabisiak TJ, Grace PM. Microglial activation mapping in sensory and affective brain regions following peripheral nerve injury. Society for Neuroscience.
- Lacagnina MJ, Fabisiak TJ, Sullivan K, O’Callaghan J, Watkins LR, Grace PM. A neuroimmune basis for chronic pain in a rat model of gulf war illness. Society for Neuroscience.
- Lacagnina MJ, Grace PM. Mapping microglial reactivity in the ‘pain matrix’ after peripheral nerve injury. American Pain Society.
- Grace PM, Lacagnina MJ, Lorca S, O’Callaghan JP. Neuroimmune signaling in a rat model of Gulf War Illness pain. IASP World Congress.
- Lacagnina MJ, Grace PM. Microglial contributions to multidimensional behaviors in neuropathic pain. IASP World Congress.
- Li J, Ma J, Kavelaars A, Grace PM. Repurposing the Nrf2 activator dimethyl fumarate (Tecfidera®) for treatment of neuropathic pain in male rats. IASP World Congress.
- Cata JP, Patiño MA, Lacagnina MJ, Agudelo-Jimenez RD, Shreiqui I, Grace PM. The impact of nutraceutical prehabilitation and postsurgical treatment with ecoisapentanoic acid and acetylsalicylic acid on a novel animal model of recovery after surgery. International Anesthesia Research Society.
- Green-Fulgham SM, Ball JB, Kwilasz AJ, Maier SF, Watkins LR, Grace PM. The opioids oxycodone, fentanyl, and morphine amplify neuropathic when given after chronic pain is established. American Pain Society:.
- Zhang Y, Kanne CK, Tran JN, Lacagnina MJ, Grace PM. Validation of a peripheral blood-derived microglia-like cell system. American Society of Hematology Annual Meeting.
- Li J, Ma J, Lorca SA, Kavelaars A, Grace PM. Anti-nociceptive role of the antioxidant transcription factor Nrf2 in neuropathic pain. Division of Internal Medicine Research Retreat.
- Lacagnina MJ, Grace PM. Antibody receptor signaling from spinal cord glial cells promotes neuropathic pain. Gulf Coast Consortium for Translational Pain Research.
- Li J, Cherry F, Shepherd AS, Grace PM. Endogenous Activation of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Alleviates Peripheral Neuropathic Pain. Gulf Coast Consortium for Translational Pain Research.
- Li J, Cherry F, Shepherd AS, Grace PM. Endogenous Activation of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Alleviates Peripheral Neuropathic Pain. Second Annual NIH HEAL Initiative Investigator Meeting.
- Li J, Cherry F, Shepherd AS, Grace PM. Endogenous Activation of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Alleviates Peripheral Neuropathic Pain. IASP Virtual World Congress on Pain.
- Lacagnina MJ, Willcox K, Li J, Alfaro AG, Lorca S, Grace PM. Antibody receptor signaling on spinal cord glial cells promotes neuropathic pain. Psychoneuroimmunology Research Society Annual Meeting.
- Li J, Cherry F, Shepherd AS, Grace PM. Endogenous Activation of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Alleviates Peripheral Neuropathic Pain. Psychoneuroimmunology Research Society Annual Meeting.
- Ur Rasheed MS, Cherry F, Grace PM. Opioid-sparing effects of the Nrf2 activator diroximel fumarate in mice. Society for Neuroscience Annual Meeting.
- Lacagnina MJ, Willcox K, Li J, Alfaro AG, Lorca S, Grace PM. Antibody receptor signaling from spinal cord astrocytes promotes neuropathic pain. Society for Neuroscience Annual Meeting.
- Rasheed MSU, Cherry FR, Grace PM. Opioid-sparing effects of the Nrf2 activator diroximel fumarate in mice. 2022 Internal Medicine Research Retreat & Poster Session.
- Zhang J, Junigan JM, Trinh RT, Heijnen CJ, Grace PM, Kavelaars A. HDAC6 inhibition reverses cisplatin-induced mechanical hypersensitivity via delta opioid receptor signaling. DoIM Research Retreat.
- Cazuza RA, Lacagnina MJ, Grace PM. Microglia activation tracking across brain regions over the development of neuropathic pain. Internal Medicine Research Retreat & Poster Session.
- Rasheed MSU, Cherry FR, Grace PM. Opioid-sparing effects of the Nrf2 activator diroximel fumarate in mice. 11th Annual GCC Translational Pain Research Conference.
- Zhang J, Junigan JM, Trinh RT, Heijnen CJ, Grace PM, Kavelaars A. HDAC6 inhibition reverses cisplatin-induced mechanical hypersensitivity via delta opioid receptor signaling. 11th Annual GCC Translational Pain Research Conference.
- Cazuza RA, Lacagnina MJ, Grace PM. Microglial activation in sensory and affective brain regions throughout neuropathic pain development. 11th Annual GCC Translational Pain Research Conference.
- Cazuza R, Lacagnina MJ, Grace PM. Microglia activation tracking across brain regions over the development of neuropathic pain. US Association for the Study of Pain Annual Meeting.
- Lacagnina MJ, Willcox K, Li J, Alfaro AG, Lorca S, Grace PM. Antibody receptor signaling from spinal cord astrocytes promotes neuropathic pain. US Association for the Study of Pain Annual Meeting.
- Cherry FR, Ur Rasheed MS, Chavez MV, Li J, Grace PM. The Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) in Preventing Inflammasome Activation in Peripheral Nerve Injury. US Association for the Study of Pain Annual Meeting.
- Cazuza RA, Lacagnina MJ, Grace PM. Microglia activation tracking across brain regions over the development of neuropathic painC. Annual Scientific Meeting for the United States Association for the Study of Pain.
- Rasheed MSU, Cherry FR, Grace PM. Opioid-sparing effects of the Nrf2 activator diroximel fumarate in mice. US Association for the Study of Pain Annual Scientific Meeting.
- Li J, Avery TD, Turner DJ, Cherry FR, Ur Rasheed MS, Lacagnina MJ, Gaffney CM, Aguilar C, Yu J, Shepherd AJ, Abell AD, Grace PM. Pathology activated prodrugs targeting Nrf2 to treat neuropathic pain. US Association for the Study of Pain Annual Meeting.
- Rasheed MSU, Cherry FR, Chavez MV, Grace PM. Diroximel fumarate protects from opioid-induced hyperalgesia and tolerance in mice. Society for Neuroscience Annual Meeting.
- Lacagnina MJ, Willcox KF, Li J, Heijnen CJ, Grace PM. Antibody receptor signaling from spinal cord astrocytes promotes neuropathic pain. Society for Neuroscience Annual Meeting.
- Willcox KF, Lacagnina MJ, Lin CY, Chavez MV, Lu JT, Zuberi YA, Heijnen CJ, Grace PM. B cells regulate initiation of neuropathic pain. Society for Neuroscience Annual Meeting.
- Willcox KF, Lacagnina MJ, Boukelmoune N, Bavencoffe A, Walters ET, Heijnen CJ, Grace PM. B cells drive mechanical pain after nerve injury. Gulf Coast Consortia 12th Annual Translational Pain Research Conference.
Book Chapters
- Hutchinson, MR, Milligan, ED, Grace, P. Dr. Linda R. Watkins. In: Brain, behavior, and immunity, 685-688, 2025.
- Grace PM. A backbone for reverse-translation: evidence for neuroimmune signaling in low back pain. In: Brain Behav Immun, 2019.
- Sterling M, Sluka KA, and Grace PM. Physical activity and exercise for pain. In: Pain 2018: Refresher Courses, 17th World Congress on Pain. Pain, 2018.
- Li J, Grace PM. Neuroimmune signaling and pain. In: The Oxford Handbook of the Neurobiology of Pain. Oxford University Press, 2018.
- Galer, EL, Grace PM. Reactive aldehydes: A new player in inflammatory pain. In: Ann Transl Med, 2015.
- Grace PM, Watkins LR, Hutchinson MR. Immune to brain communication in pain: historical perspectives, new directions. In: The Wiley-Blackwell Handbook of Psychoneuroimmunology. Wiley-Blackwell, 176-97, 2014.
- Grace PM, Watkins LR, Hutchinson MR. The role of the immune system in chronic pain comorbidities. In: Pain Comorbidities: Understanding and Treating the Complex Patient. IASP Press, 2012.
- Grace PM. The anatomical distribution of trigeminal neuralgia: a perspective and future directions. In: Anesth Pain Med, 2012.
Web Publications
- Grace PM. Microglia: gatekeepers for neuropathic pain, 2018.
- Grace PM. Do opioids make pain worse?, 2016.
- Grace PM. Learning the lessons of networking, 2016.
Patents
- Methods and Compositions to Enhance the Anti-Inflammatory Effects of Interleukin 10. Patent Number: PCT/US17/28755.
Patient Reviews
CV information above last modified August 03, 2026